Table 3– Treatment outcomes of multidrug-resistant tuberculosis (TB) patients, excluding those not treated with linezolid, enrolled in two specialised clinical centres in Italy and the Netherlands after 30, 60 and 90 days of treatment
VariablesItalian cohort: cases#Dutch cohort: controlsp-value
Sputum-smear conversion
 At 30 days of treatment5/28 (17.9)9/18 (50.0)0.02
 At 60 days of treatment17/28 (60.7)7/16 (43.8)0.28
 At 90 days of treatment24/28 (85.7)9/16 (56.3)0.03
Sputum-culture conversion
 At 30 days of treatment9/32 (28.1)12/29 (41.4)0.28
 At 60 days of treatment20/32 (62.5)13/25 (52.0)0.43
 At 90 days of treatment26/32 (81.3)15/24 (62.5)0.12
Days from start of anti-TB therapy to sputum smear conversion52.5 (42.0–65.0)46.0 (6.0–157.0)0.80
Days from start of anti-TB therapy to culture conversion42.0 (28.0–77.0)46.0 (13.0–96.0)0.79
  • Data are presented as n/N (%) or median (interquartile range), unless otherwise stated. #: meropenem–clavulanate containing anti-TB regimen; : meropenem–clavulanate-sparing anti-TB regimen.